We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Nimbus Announces Change to Business Board

Nimbus Announces Change to Business Board

Nimbus Announces Change to Business Board

Nimbus Announces Change to Business Board

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nimbus Announces Change to Business Board"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nimbus Biotechnology has reported a change to the company’s Supervisory Board. Professor Axel Kleemann, formerly executive board member of Asta Medica AG has been appointed as a new member and chairman of the Supervisory Board.

Professor Thomas Bayerl, Dr. Rainer Strohmenger (Wellington Partners Venture Capital GmbH, Germany), Jack Griffin and Mario Ober (CFH, Germany) continue to be board members.

Nimbus Biotechnology thanks Werner Zollner (Seed GmbH, Germany) for his former work and support in this position.

Wolfgang Lerch, CEO of Nimbus Biotechnology, stated, "The appointment of Professor Axel Kleemann is a very special opportunity for Nimbus Biotechnology."

"With his expertise we will strengthen our mission to support our customers with cutting-edge tools."

"We will come closer to developing modern tools for all stages of drug discovery. All employees of the company wish him success for his work."